An Entity of Type: Thing, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

The Mesomark Assay is an in vitro test to monitor and possibly diagnose pleural mesothelioma and peritoneal mesothelioma. Developed by Fujirebio Diagnostics and approved in late January 2007 by the U.S. Food and Drug Administration (FDA), it works by measuring levels of soluble mesothelin-related proteins (SMRPs) released by diseased mesothelioma cells. The SMRP levels correlate directly with tumor volume thus permitting less invasive monitoring and improved assessment of treatment response.

Property Value
dbo:abstract
  • The Mesomark Assay is an in vitro test to monitor and possibly diagnose pleural mesothelioma and peritoneal mesothelioma. Developed by Fujirebio Diagnostics and approved in late January 2007 by the U.S. Food and Drug Administration (FDA), it works by measuring levels of soluble mesothelin-related proteins (SMRPs) released by diseased mesothelioma cells. The SMRP levels correlate directly with tumor volume thus permitting less invasive monitoring and improved assessment of treatment response. The MESOMARK assay is the most well-known and the world's first blood serum-based test for diagnosing mesothelioma. However, as certain types of tumors (such as sarcomatoid mesothelioma) do not release SMRP, the FDA recommends that doctors use the MESOMARK assay in conjunction with other tests to ensure an accurate mesothelioma diagnosis. In the future, the test may be used as an early detection measure as evidenced by recently sponsored tests by the Early Detection Research Network of the National Cancer Institute [1]. (en)
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 10018781 (xsd:integer)
dbo:wikiPageLength
  • 2636 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 984456525 (xsd:integer)
dbo:wikiPageWikiLink
dbp:name
  • Mesomark assay (en)
dbp:purpose
  • diagnose of Pleural Mesothelioma and Peritoneal Mesothelioma (en)
dbp:wikiPageUsesTemplate
dcterms:subject
rdfs:comment
  • The Mesomark Assay is an in vitro test to monitor and possibly diagnose pleural mesothelioma and peritoneal mesothelioma. Developed by Fujirebio Diagnostics and approved in late January 2007 by the U.S. Food and Drug Administration (FDA), it works by measuring levels of soluble mesothelin-related proteins (SMRPs) released by diseased mesothelioma cells. The SMRP levels correlate directly with tumor volume thus permitting less invasive monitoring and improved assessment of treatment response. (en)
rdfs:label
  • Mesomark assay (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License